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NLRP3 inflammasome is a multiprotein complex playing a key role in the intracellular 
activation of the innate immune system through activating cleavage of pro-inflammatory 
interleukins (IL)-1β, IL-18 and triggering of pyroptotic cell death1. In the last decades, several 
studies have highlighted the pivotal role of inflammasomes in the molecular control of 
inflammatory processes and the pathological role of NLRP3 inflammasome has been well 
established in different pathological settings.  
 
Aims 
The discovery of agents able to prevent inflammasome activation is a promising therapeutic 
strategy to decrease chronic inflammation and associated damage. 
 
Methods 
NLRP3 and few others inflammasome possess ATP-binding potential and intrinsic ATPase 
activity. Mutations in ATP-binding regions abolished their ATP-binding and ATPase activities 
and thereby resulted in impaired IL-1β maturation. From a screening of different molecular 
fragments on recombinant human (rh)NLRP3 protein, a benzo[d]imidazol-1-one sub-moiety 
was identified as a weak inhibitor of ATPase activity. The fragment was functionalized using 
other structural motifs present in derivative INF39, previously identified as able to bind to 
NLRP3 and to hamper ATPase activity2. Modulation of selected molecular moieties (Structure 
1: A; B; X; W; Z; R1, R2) was performed using classical medicinal chemistry techniques such 
as bioisosteric replacement and refining of conformational flexibility. 
 
 
Results / Conclusions 
Newly synthesized compounds showed 5-10-fold improved NLRP3 ATPase inhibition with 
respect to starting fragments. INF97 elicits an interesting concentration-dependent ATPase 
inhibition (IC50: 17.2 μM, 15.4 – 19.2 C.L. 95%) and inhibits LPS/ATP triggered pyroptosis. 
Using a fragment-based approach, new NLRP3 ATPase inhibitors were obtained, and a new 
non-covalent hit compound (INF97) has been identified and characterized.  
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